Priscilla Y. Hsue awarded $6.3 million grant to lead multicenter trial investigating GLP-1 therapy in HIV patients

Dr. Priscilla Hsue
Dr. Priscilla Hsue is Chief of the Division of Cardiology.

The National Heart, Lung and Blood Institute (NHLBI) has awarded an R01 grant for $6.3 million to Dr. Priscilla Y. Hsue, professor of medicine and chief of the UCLA Health’s division of cardiology, to lead the Olympic-HIVTrial, a multicenter study investigating how glucagon-like peptide-1 receptor agonists (GLP-1RAs) may reduce inflammation and atherosclerosis in people living with HIV.

People living with HIV experience a significantly higher burden of cardiovascular disease, driven in part by chronic inflammation and immune activation. Although GLP-1 therapies have been shown to reduce cardiovascular events in the general population, researchers do not yet fully understand the biological mechanisms behind these benefits. The Olympic-HIV Trial seeks to address that gap by examining how these medications affect the underlying pathways of inflammation and atherosclerosis in people living with HIV.

“It's humbling to reflect that the initial idea for this study came from early conversations in late 2023. We worked with NHLBI to refine the proposal and submitted it in 2025, and our team is excited and grateful to finally begin this study here at UCLA,” said Hsue.

Importantly, this will be the first study to evaluate the impact of a GLP-1 therapy on both arterial inflammation and non-calcified coronary plaque in people living with HIV. Beyond advancing understanding of cardiovascular disease in HIV, the findings could help explain why GLP-1 therapies improve cardiovascular outcomes more broadly, potentially supporting their use among individuals with chronic inflammatory conditions and other populations at elevated risk for heart disease.

Hsue noted that understanding how GLP-1 therapies improve cardiovascular outcomes – independent of their effects on weight loss and glucose control – could have implications beyond HIV care. “If successful, this study could broaden the use of these agents in HIV and potentially support their use in other populations with chronic inflammation or elevated cardiovascular risk,” she said.

The study will enroll participants aged 40 and older with at least one cardiovascular risk factor and randomize them to receive either an oral GLP-1 medication or placebo for 52 weeks. Investigators will evaluate changes in arterial inflammation, coronary plaque burden, systemic inflammation, immune activation and cardiometabolic health using advanced multimodal imaging and biomarker analyses. The trial will bring together leading expertise in HIV and cardiovascular research from across the country.

Book An Appointment

See a doctor, virtually or in-person, with our easy online booking options.

Related Content

Physician

UCLA Health logo on a sand-colored background with a circular sun rising in the right corner.
Priscilla Y. Hsue, MD
Cardiology
Priscilla Y. Hsue, MD

Media Contact

Rocio Cruz
[email protected]